AGEN

Agenus

• NASDAQ·04/03 16:20

  Can Agenus (AGEN) Run Higher on Rising Earnings Estimates?

• NASDAQ·04/03 13:50

  Why Agenus (AGEN) is a Top Momentum Stock for the Long-Term

• Reuters·04/03 11:30

  Agenus to present Phase II BOT+BAL plus agenT-797 data in PD-1 refractory GEC at AACR

• Reuters·04/03 11:30

  AGENUS ANNOUNCES DATA FROM PHASE II STUDY OF BOT+BAL IN COMBINATION WITH AGENT-797 IN PD-1 REFRACTORY GASTROESOPHAGEAL CANCER TO BE PRESENTED AT AACR 2026

• Benzinga·04/01 11:35

  Agenus Announces First Patient Enrolled In Global Phase 3 BATTMAN Trial

• Reuters·04/01 11:30

  Agenus enrolls first patient in Phase 3 BATTMAN trial for BOT+BAL in MSS mCRC

• Reuters·04/01 11:30

  AGENUS ANNOUNCES FIRST PATIENT ENROLLED IN GLOBAL PHASE 3 BATTMAN TRIAL OF BOT+BAL IMMUNOTHERAPY COMBINATION IN MSS OR PMMR METASTATIC COLORECTAL CANCER

• TipRanks·04/01 10:15

  Agenus: Strengthening Bot/Bal Clinical Profile and Capital-Efficient Path to Registration Underpin Positive Rating

• TipRanks·03/27 16:32

  Agenus Cervical Cancer Trial Terminated: What RaPiDS Means for AGEN Investors

• Reuters·03/26 20:57

  Agenus to host stakeholder webcast on BOT+BAL immunotherapy program; Q&A to follow live session

• TipRanks·03/26 12:59

  Agenus Securities Class Action Dismissed, Legal Risks Ease

• Reuters·03/26 12:25

  Agenus securities class action dismissed in full; Massachusetts federal court denies leave to amend

• Reuters·03/19 21:22

  Mink Therapeutics names Melissa Orilall principal financial officer and Austin Charette principal accounting officer

• Benzinga·03/17 20:40

  Agenus To Present Chemo-Sparing BOT+BAL Immunotherapy Data In 1L MSS Colorectal Cancer At AACR 2026

• Reuters·03/17 20:40

  Agenus to present preliminary BOT+BAL first-line MSS metastatic colorectal cancer data at AACR 2026